A groundbreaking study reveals that a blood test can identify Alzheimer's patients at risk of rapid decline. Researchers highlight the importance of insulin resistance in accelerating cognitive impairment, opening doors for timely interventions.
Richard Schlueter, battling metastatic cancer, faces a desperate wait for experimental treatment as NIH staff cuts delay his therapy. His story sheds light on the critical impact of workforce reductions on patient care.
A new study indicates that a single dose of psilocybin can alleviate depression for up to five years, offering hope for those with major depressive disorder. This groundbreaking research highlights the potential of psychedelics in mental health treatment.
Recent research suggests that psilocybin, the active compound in magic mushrooms, may alleviate depressive episodes in bipolar II disorder, showing promise without triggering mania. The trial found significant improvements among participants, indicating a potential new treatment avenue.
A new phase 2 trial reveals that a single dose of psilocybin, combined with psychological support, significantly reduces depression in over half of cancer patients, lasting up to two years.
A new clinical trial shows that a single dose of psilocybin can significantly reduce depression and anxiety in cancer patients. With promising long-term results, this therapy offers hope for many.
In a bold move, over 90 NIH scientists have signed the Bethesda Declaration, challenging their new leader Jay Bhattacharya and the Trump administration's policies that threaten public health research and safety.
A groundbreaking study shows that regular exercise can significantly lower the risk of colon cancer recurrence, rivaling traditional chemotherapy treatments. Discover how a simple exercise routine can save lives!
A groundbreaking study reveals that exercise can reduce cancer patients' risk of death by 37% and recurrence by 28%, proving it's even more effective than many drugs. This landmark trial could reshape health guidelines globally.
In a surprising move, the HHS has terminated a $590 million contract with Moderna for H5 avian influenza vaccine development, raising alarms among health experts amidst rising H5N1 threats.
